Avastin use restricted

Bevacizumab blocks the action of VEGF, thus inhibiting angiogenesis
Bevacizumab blocks the action of VEGF, thus inhibiting angiogenesis

Use of bevacizumab (Avastin) in patients with metastatic breast cancer has been restricted to combination therapy with the taxane, paclitaxel.

The antibody was previously also licensed for use with another taxane, docetaxel. However, new data submitted to the Committee for Medicinal Products for Human Use showed that the combination of bevacizumab with docetaxel has a smaller effect on progression-free survival than previously thought, and may even reduce overall survival. Accordingly, use of this combination is no longer recommended.

The Committee concluded that the risk-benefit balance for combination use of bevacizumab with paclitaxel remains positive.

The other indications of Avastin, including non-small cell lung cancer, colorectal cancer and renal cell carcinoma, are unaffected by the change.

View Avastin drug record

Further information: Roche

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic guidance for diabetic foot infection

New antibiotic guidance for diabetic foot infection

NICE has updated its guidance on the prevention and...

Drug shortages - live tracker

Drug shortages - live tracker

Added: co-fluampicil.
Use our constantly updated...

Further drug shortages prompt advice to consider unlicensed alternatives

Further drug shortages prompt advice to consider unlicensed alternatives

Prescribers are being advised to prioritise supplies...

Vaping still safer than smoking, say health bosses after report of severe lung injury